Opko Health Inc. (NASDAQ:OPK) – Stock analysts at Barrington Research reduced their FY2022 EPS estimates for shares of Opko Health in a research note issued to investors on Monday, November 12th. Barrington Research analyst M. Petusky now forecasts that the biotechnology company will post earnings of $0.31 per share for the year, down from their previous forecast of $0.33. Barrington Research has a “Buy” rating and a $7.00 price objective on the stock.

OPK has been the subject of a number of other reports. BidaskClub cut Opko Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 8th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price target on shares of Opko Health in a report on Tuesday, August 7th. Finally, ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. Opko Health presently has an average rating of “Hold” and an average target price of $9.69.

Shares of OPK stock opened at $3.49 on Wednesday. The company has a quick ratio of 0.90, a current ratio of 0.91 and a debt-to-equity ratio of 0.03. Opko Health has a 12 month low of $2.66 and a 12 month high of $6.40. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -12.03 and a beta of 1.89.

Opko Health (NASDAQ:OPK) last announced its earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03. Opko Health had a negative return on equity of 8.68% and a negative net margin of 30.24%. The firm had revenue of $250.00 million during the quarter, compared to the consensus estimate of $264.04 million. During the same quarter in the prior year, the company earned ($0.08) EPS. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year.

In other news, CEO Phillip Md Et Al Frost acquired 15,000 shares of the firm’s stock in a transaction on Friday, August 24th. The shares were purchased at an average cost of $5.70 per share, for a total transaction of $85,500.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $17,493,020.70. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders acquired a total of 55,000 shares of company stock worth $313,000 over the last quarter. Corporate insiders own 42.74% of the company’s stock.

Large investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd bought a new position in Opko Health during the third quarter worth about $925,000. GSA Capital Partners LLP lifted its holdings in Opko Health by 17.1% during the third quarter. GSA Capital Partners LLP now owns 317,500 shares of the biotechnology company’s stock worth $1,099,000 after acquiring an additional 46,422 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Opko Health by 136.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 498,896 shares of the biotechnology company’s stock worth $1,726,000 after acquiring an additional 288,114 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Opko Health by 25.3% during the third quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock worth $15,363,000 after acquiring an additional 897,406 shares in the last quarter. Finally, Virtu Financial LLC lifted its holdings in Opko Health by 93.9% during the third quarter. Virtu Financial LLC now owns 67,363 shares of the biotechnology company’s stock worth $503,000 after acquiring an additional 32,629 shares in the last quarter. Institutional investors and hedge funds own 24.87% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Recommended Story: Bull Market

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.